Pharmacological aspects of cognitive impairment: past, present and future of drugs in dementia

Abstract

Cognitive impairment is a dramatically increasing problem affecting many individuals as well as the health system. As we have no causal treatment for the loss of memory, symptomatic treatment is needed. Influencing the ACh system is a generally accepted approach, although other therapeutic treatments are in various stages of development. The multiple target drug approach using hybrid compounds may be another optimized move forward for the treatment of cognitive disorders. Since the complex neuronal regulation is slowly being decoded, there is hope that ways will be found to stop neuronal loss and to generate new synapses.

[3-[(1-Methylpiperidin-4-yl) methyl] arylsulfonyl]-1H-indoles: Synthesis, SAR and biological evaluation as a novel class of 5-HT6 Receptor Antagonists

“…Infrared spectra were recorded on KBr disk and in solid state using Perkin-Elmer model 1600 FT-IR spectrophotometer (Perkin-Elmer, Norwalk, CT, USA). 1 H NMR spectra were obtained on a Bruker NMR spectrometer (Fallanden, Switzerland) at 400 MHz. Deuterated reagents were used as solvents and were commercially procured.…”

“…IR (cm −1 ): 3410 (broad, due to -OH stretching vibrations of -COOH group) and ∼1313 and 1182 (sharp, strong, due to asymmetric and symmetric stretching vibrations of -SO 2 group respectively). 1 benzenesulfonyl]-1H -indole, that is, compound 9a. This compound displayed a potent affinity with an inhibition of 97.49% towards 5-HT R. We then introduced selective substitutions like methyl and methoxy at R 2 position of Compounds I and synthesized 9b and 9c respectively.…”

“…Cognitive decline is a defining symptom of many severe neurological disorders, viz., Alzheimer's disease (AD), Schizophrenia, Parkinson's disease (PD), etc. 1 The current options to treat cognitive symptoms associated with neurological disorders mentioned above include drugs like Donepezil 2 and Memantine. 3 These drugs have limited efficacy and poor tolerability.…”